Original article

Title

Clinical course of COVID-19 patients admitted to the Intensive Care Unit of a tertiary care hospital in Central India

Dr Alka Modi Asati^{* 1}, Dr Rakesh Patel², Dr Kritika Singhal³, Dr Chakresh Jain⁴

1. Senior resident, Department of Community and Family medicine, AIIMS, Bhopal, <u>asati.dr@gmail.com</u>

2. Associate Professor, Department of Medicine, SSMC Rewa, <u>dr.rakeshpatel11@gmail.com</u>

3. Senior resident, Department of Community and Family medicine, AIIMS, Bhopal, kritikasinghal0502@gmail.com

4. Assistant Professor, Department of Medicine, SSMC Rewa,

drchakreshjain81@gmail.com

Corresponding author

Dr. Alka Modi Asati

Email: asati.dr@gmail.com.

Mobile number: 8226052424

Address: Department of Community and Family Medicine, 2nd floor, Sardar Vallabhai Patel Bhawan, AIIMS, Saket Nagar, Bhopal, MP-462020.

Author approval

All the authors have seen and approved the manuscript.

Competing interests

There are no competing interests.

Funding statement

This study had no source of funding.

Abstract:

Background: COVID-19 pandemic also known as Corona virus pandemic, is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2). In India, the first case of COVID-19 was reported on 30 January 2020 while in Madhya Pradesh on 20 March 2020 and in Rewa on 27 April 2020. Nearly 95 % of people recovered from COVID-19, and nearly three to five percent of cases needed Intensive Care Unit care and most of them needed mechanical ventilation.

Materials and Methods: This was a hospital based cross-sectional study, done among 75 clinical or RT-PCR confirmed cases of COVID-19 infection admitted to the ICU of tertiary care unit.

Results: In the present study, 63% were male and maximum (35%) belonged to 41-60 years of age. The most common symptom was fever at the time of admission to the hospital. Co-morbidity was reported in 21(28%) of patients. Out of these, majority of patients recorded combination of hypertension and diabetes as the most common comorbidity.

Conclusion: Delayed medical intervention, advanced age, and the presence of underlying health conditions, such as cardiovascular disease, diabetes, etc., are known risk factors for severe illness and can contribute to worse outcomes and increased mortality in COVID-19 patients.

Keywords: COVID -19, Covid mortality, comorbidity, ICU Outcome, Pneumonia, Tertiary care

Introduction

The COVID-19 pandemic has affected millions of people globally, with many requiring hospitalization and intensive care unit (ICU) treatment. ICU treatment is necessary for patients with severe COVID-19 symptoms, including respiratory failure, pneumonia, and other complications. This infection started in China in December 2019 and became a pandemic, caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV 2). (1) In India, the first case of COVID-19 was reported on 30 January 2020.(2) first wave of the COVID pandemic in India lasted from January to November 2020. ,While a few cases kept appearing, the second wave evolved from February - July 2021. (3)

Till May 2021, more than 164 million confirmed cases and more than 3.4 million deaths attributed to COVID-19. (3) Nearly 95 % of people recovered from Covid-19, and around 3 to 5 percent of cases required ICU care (2) including mechanical ventilation. COVID-19 pandemic has affected many aspects of people's life including physical, social, emotional and behavioral wellbeing. To halt the spread of SARS-CoV-2 infection and alleviate its health effects, country had enforced different control measures, like social distancing, partial and total lockdowns, closing schools and businesses and wearing face masks. Although such measures have helped in flattening the epidemic curve, a COVID-19 resurgence has been reported after resuming all public activities. This increased morbidity and mortality associated with COVID-19 especially during the second wave.(2,4) The COVID-19 vaccine development was an important step towards controlling the pandemic. India's COVID Vaccination drive was started on January 16, 2021, in a phased manner. (5) Even after all this, many people were seriously affected and were admitted in hospitals, especially during the second wave. Most of these patients were admitted to the Intensive Care Units and would eventually require invasive mechanical ventilation (MV) because of diffuse lung injury and acute respiratory distress syndrome (ARDS). Most of the ICU reports from the United States have shown that severe COVID-19-associated ARDS (CARDS) is associated with prolonged MV and increased mortality.(6) There may be institutional and regional variations in ICU outcomes and mortality. The unsatisfactory ICU outcomes and high mortality observed during CARDS have raised worries about the use of mechanical ventilation. India, now with the largest population in the world, had difficulty in treating severe COVID-19 cases because the country had only 49,000 ventilators (6). This disproportionate availability of resources led to different types of outcomes in COVID-19 patients, this study throws light on the clinical course of COVID-19 patients in the tertiary care units with the objective of clinical characteristics and outcomes of COVID-19 patients admitted to ICU.

Material & Methods

This study was a hospital based cross sectional study which was conducted for a period of one month in May 2021. Universal sampling technique was applied to select the participants. All the patients admitted to the ICU of a tertiary care hospital were approached and consent was taken from patients or their attendant. A total of 75 RT-PCR positive or clinically diagnosed (CT scan findings suggestive of COVID) patients were included in the final analysis. The study tool was a structured proforma, which was designed, validated and used for data collection. Information was collected from various sources including treatment sheet, patients, and their attendant. All patients admitted to ICU for COVID-19 treatment, and more than 12 years of age were included in the study. Data related to socio- demography, clinical characteristics and laboratory parameters were collected.

Statistical analysis: Continuous data were presented as median and IQR, Frequency and percentages (n; %) were used for categorical variables. Appropriate test applied wherever necessary. Analysis was done with R software (4.3.1) and Microsoft excel.

Ethical consideration: The study was conducted after taking ethical approval from the institutional ethical committee of Sham Shah Medical College, Rewa, Madhya Pradesh. This study was approved by the committee with permission letter numbered IEC/MC/2020470. Confidentiality was maintained by removing identifiers during analysis and reporting of results. Data was collected only after due informed consent/assent.

Result

Out of 75 patients admitted to the ICU, mean age of the patients was 53.66 (\pm 17.19) years. Maximum number of participants (35%) belonged to the 41-60 years age group followed by 21-40 years (31%). Most of the study participants were residents of rural area. Sociodemographic characteristics are presented in Table 1.

1

Sociodemographic	N = 75 (%)	
Characteristic		
Age	·	
<20	6 (8.0%)	
20-40	23 (31%)	
41-60	26 (35%)	
>60	20 (27%)	
Sex	•	
Female	28 (37%)	
Male	47 (63%)	
Locality	•	
Rural	49 (65%)	
Urban	26 (35%)	

Table 1: Socio-demographic characteristics of patients

Out of 75, only 48 (64%) patients gave the history of close contact with any COVID-19 positive individual and 68% of the patients were found positive for COVID-19 infection. Although 32% patients were COVID-19 negative, but their clinical status was strongly suggestive of COVID-19 on CT scan. Table 2 depicts the clinical characteristics of the participants.

Variables	n (%)
COVID-19 test	
Negative	24 (32%)
Positive	51 (68%)
Symptoms of patients at the time	e of admission in Hospital
Fever	24 (32%)
Breathlessness	14 (18.6%)
Fever with chills	12 (16%)
Cough	08 (10.7%)
Generalized	06 (08%)
weakness	
Altered Sensorium	04 (5.3%)
Loss of appetite	03 (04%)
Pain in abdomen	03 (04%)
Diarrhoea	01 (1.3%)
Number of co morbidities	
No	54 (72%)
1	11 (15%)

2	9 (12%)	
3	1 (1.3%)	
Type of Co morbidity (n= 21)	•	
Diabetes	03 (14.2%)	
Hypertension	04 (19%)	
Diabetes+	05 (23.8%)	
Hypertension		
Coronary artery	02 (9.5%)	
disease		
Pulmonary disease	02 (9.5%)	
Others#	05 (23.8%)	
Outcome		
Alive	29 (39%)	
death	46 (61%)	
Duration of stay in ICU (days) ((4(3.0,8.0)) *	
≤3 days	34 (45%)	
4 TO 7	21 (28%)	
814	14 (19%)	
>14	6 (8.0%)	
Requirement of Mechanical ven	tilation	
Yes	21 (28%)	
No	54 (72%)	

*Median (IQR); #Thyroid disorder, Malignancy, morbid obesity, seizer disorder, severe anemia

Symptoms during admission to the hospital, were fever (32%), followed by breathlessness (18.6%) and cough (10.7%). In the current study, around 28% of patients had any comorbidity. Out of that 52.4% of patients experienced at least one comorbidity (Table 3). Hypertension (19% patients reported) was most common comorbidity followed by diabetes (14.2%) whereas hypertension and diabetes were the most common (23.8%) combination comorbidity reported. In view of duration of stay in ICU, most of the patients (45%) were admitted for less than 3 days to ICU. A total of 28% required mechanical ventilation. With respect to outcomes, 39% alive and 61% patients expired at the end of the study period.

Parameter	N (%)	
Haemoglobin*	12.00 (10.00, 13.65)	
Anaemia		
No	30 (40%)	
Mild	18 (24%)	
Moderate	24 (32%)	
Severe	3 (4.0%)	
WBC*	12,000 (9,300,	
	15,800)	
PLATELET*	126,000 (112,000,	
	179,500)	
Platelet		
Normal	59 (79%)	
Thrombocytopenia	16 (21%)	
CRP		
Negative	28 (37%)	
Positive (raised)	47 (63%)	
D DIMER	•	
≤0.5	8 (11%)	
>0.5	67 (89%)	
HRCT SCORE*	17.0 (14.5.0, 21.0)	
<8 (Mild)	01 (1.3%)	
8-15 (Moderate)	28 (37.34%)	
>15 (Severe)	46 (61.34%)	
Disease severity status#	•	
Mild to moderate	36 (48%)	
Severe	39 (52%)	

Table 3: Laboratory investigations of patients at the time of admission in ICU:

* Median (IQR); #Disease severity status=Severe disease was defined as either of these,

i.e., RR >24/min, SpO2 <94 per cent on room air, confusion, drowsiness, hypotension, sepsis, septic shock or admission to ICUs (7).

Table 4 shows association of outcome of patients with their sociodemographic and clinical characteristics. Maximum patients from age group > 60 years expired but this result was not significant. Only duration of stay in ICU and HRCT Score showed significant association with outcome. Figure 1 pictorially depicts the distribution of clinical and demographic characteristics across the clinical outcome through a stacked bar chart.

Table 4: Distribution of patient outcomes across sociodemographic and clinical characteristics

Characteristic	Alive , $(N = 29)$	death , (N = 46)	p-value ¹
Age		0.1	49
<20 years	1 (3.4%)	5 (11%)	
20-40	9 (31%)	14 (30%)	
40-60	14 (48%)	12 (26%)	
>60	5 (17%)	15 (33%)	
sex	I		0.933
Female	11 (38%)	17 (37%)	
Male	18 (62%)	29 (63%)	
Address			0.974
Rural	19 (66%)	30 (65%)	
Urban	10 (34%)	16 (35%)	
COVID-19 test	· · · ·		0.714
Negative	10 (34%)	14 (30%)	
Positive	19 (66%)	32 (70%)	
Duration of stay in hospital (days)		0.001	
≤3days	8 (28%)	26 (57%)	
4 TO 7	16 (55%)	5 (11%)	
814	5 (17%)	9 (20%)	
>14	0 (0%)	6 (13%)	
Number of Comorbidities			0.177
No	25 (86%)	29 (63%)	
1	2 (6.9%)	9 (20%)	
2	2 (6.9%)	7 (15%)	
3	0(0%)	1 (2.2%)	
Heamoglobin*	11.20 (10.00, 13.80)	12.00 (10.58, 13.00)	0.7
Aneamia			0.332
No	12 (41%)	18 (39%)	
Mild	4 (14%)	14 (30%)	
Moderate	12 (41%)	12 (26%)	
Severe	1 (3.4%)	2 (4.3%)	
WBC*	13,000 (11,000,	11,000 (8,300, 16,200)	0.036
	13,300)		
Platelet*	118,300	140,000	0.2
	(118,000,176,000)	(110,500,180,000)	
Platelet			0.637
Normal	22 (76%)	37 (80%)	
Thrombocytopenia	7 (24%)	9 (20%)	

CRP			0.286
Negative	13 (45%)	15 (33%)	
Positive	16 (55%)	31 (67%)	
D DIMER		0.049	
≤0.5	6 (21%)	2 (4.3%)	
>0.5	23 (79%)	44 (96%)	
HRCT SCORE ^{\$}	15.0 (13.0, 17.0)	20.0 (17.0, 22.0)	< 0.001
Mild (<8)	0 (0%)	1 (2.2%)	
Moderate (8-15)	20 (69%)	8 (17%)	
Severe (>15)	9 (31%)	37 (80%)	

*Median (IQR); ¹ Wilcoxon rank sum exact test, Fisher's exact test, Pearson's Chi-squared test, Wilcoxon rank sum test wherever applicable; HRCT: High resolution computed tomography




Figure 1: Clinical Outcome across sociodemographic and clinical characteristics.

Discussion: Our study reported the sociodemographic characteristics, clinical profile, and outcomes of the 75 patients admitted to ICU for COVID-19 infection during the month of May 2021 in the tertiary care hospital. Compared with other studies, the mean age of study participants was almost similar i.e., 53.66 years in our study and 59 and 64 years in the study of Sweden and Atlanta respectively. (8,9) This study reported that age and gender were not significantly associated with higher

mortality. Similar results were reported in a study conducted in Saudi Arabia. (10) However, a study conducted in Sweden reported that age was significantly and gender was not significantly associated with mortality. (7) Most of our study participants were male. Around 68.8% participants experienced at least one comorbidity in a study conducted by A. Assiri et al. (10) where as in our study only 28% patients experienced any comorbidity. Hypertension was most common comorbidity followed by diabetes. Similarly in a study conducted in Sweden hypertension (39.6%) and diabetes (26.2%) were found to be the most prevalent comorbidity. (8) Auld et al reported that hypertension (61.7%) was most common followed by diabetes (45.6%) .(9) The most prevalent symptom found was fever (32%), followed by breathlessness (18.6%) and cough (10.7%) at the time of admission to the hospital in the current study. Similar results were found in a study conducted in Nanjing, China where most common symptoms were fever, dry cough followed by dyspnea. Further, cough (34.7%) was the most common symptom followed by fever (17.4%) in a study conducted in North India. (7) In our study 28% required mechanical ventilation, in contrast to 76% and 83.2% respectively in a study conducted by Auld et al (8) and Oliveira E et al. (11) Inadequate resources, technical capacity and early deaths might be the reason for this low proportion of patients requiring mechanical ventilation. A study from Sweden reported that 30.3% patients died and 31.3% were discharged. (8) Similarly, a study from Atlanta reported that 28.6% patients died in the ICU, 67.7% were transferred out of the ICU and 3.7% remained in the ICU. (9) A Central Florida study reported that out of 131 patients admitted to the ICU, 80.2% remained alive at the end of the study period, 70.9 % were discharged from the hospital and 19.8% of patients expired. (11) In contrast, our study reported higher deaths in the ICU due to COVID-19, i.e.,61% died. Our study reported a higher mortality than other literature. The reason behind this high mortality may be a delay in arrival of patients to the health facility, delays in treatment due to overcrowded health facilities, exhausted healthcare workers, inadequate training, etc. Further, presentation of patients with severe infection or end stage disease might also be a reason. Around the world, ICU mortality due to COVID-19 ranged from 20–62%. (11) In view of the duration of stay in the ICU, maximum (48%) were admitted for less than or equal to 3 days. The mean duration of stay in ICU was less in our study than the studies conducted in Florida and Sweden. (7,10) This may be due to the facility being a tertiary care institute, so patients with severe symptoms or end stage disease were admitted in a higher proportion.

Limitation: We conducted a study on only for one month and during the second wave of COVID-19 epidemic in India, hence consent was difficult to obtain due to high number of deaths. The result cannot be generalized as the study was conducted in a hospital setting.

Recommendation: It is needed to empower the health facility to accommodate a cohort of critically ill patients in one location. Appropriate training related to triage of patients, use of personal protective equipment and development of Standard of procedures for treatment are required for providing proper care to patients.

Conclusion: Second wave of COVID-19 -, presented with 41-60 years of age, male gender, and comorbidities as risk factor for severe disease and admission to ICU. Preventive measures should be emphasized on population with such risk factors to prevent COVID-19 and associated mortality in them.

Reference:

- Gorbalenya AE, Baker SC, Baric RS, Groot RJ, de Drosten C, Gulyaeva AA, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. (2020) 5:536–44. doi: 10.1038/s41564-020-0695-z.
- Andrews M, Areekal B, Rajesh K, Krishnan J, Suryakala R, Krishnan B, et al. First confirmed case of COVID-19 infection in India: A case report. Indian J Med Res [Internet]. 2020 [cited 2022 Jun 1];151(5):490. Available from: https://journals.lww.com/ijmr/Fulltext/2020/51050/First_confirmed_case_of_CO VID_19_infection_in.17.aspx
- 3. https://www.worldometers.info/coronavirus/#countries.
- 4. Breaking News March 20: Madhya Pradesh reports first Covid-19 positive cases.
- 5. https://www.hindustantimes.com/india-news/covid19-in-india-next-phase-of-vaccine-drive-kick-starts-today-101614552866500.html.
- Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020. Epub 2020/04/23. pmid:32320003.
- Mohan A, Tiwari P, Bhatnagar S, Patel A, Maurya A, Dar L, et al. Clinicodemographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north India. Indian J Med Res [Internet]. 2020 [cited 2022 Jun 16];152(1):61. Available from:https://journals.lww.com/ijmr/Fulltext/2020/52010/Clinico_demographic_p rofile hospital outcomes of.9.aspx
- 8. Larsson E, Brattström O, Agvald-Öhman C, Grip J, Campoccia Jalde F, Strålin K, et al. Characteristics and outcomes of patients with COVID-19 admitted to

ICU in a tertiary hospital in Stockholm, Sweden. Acta Anaesthesiol Scand [Internet]. 2021 Jan [cited 2022 Jun 16];65(1):76–81. Available from: https://onlinelibrary.wiley.com/doi/10.1111/aas.13694

- Auld SC, Caridi-Scheible M, Blum JM, Robichaux C, Kraft C, Jacob JT, et al. ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019*. Crit Care Med [Internet]. 2020 Sep [cited 2022 Jun 16];48(9):e799–804. Available from: https://journals.lww.com/10.1097/CCM.00000000004457
- Assiri A, Iqbal MJ, Mohammed A, Alsaleh A, Assiri A, Noor A, et al. COVID-19 related treatment and outcomes among COVID-19 ICU patients: A retrospective cohort study. J Infect Public Health [Internet]. 2021 Sep [cited 2022 Jun 16];14(9):1274–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1876034121002495
- Oliveira E, Parikh A, Lopez-Ruiz A, Carrilo M, Goldberg J, Cearras M, et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. El-Tahan MR, editor. PLOS ONE [Internet]. 2021 Mar 25 [cited 2022 Jun 16];16(3):e0249038. Available from: https://dx.plos.org/10.1371/journal.pone.0249038